JP2014041096A - Life-style related disease determination support method using saliva examination - Google Patents
Life-style related disease determination support method using saliva examination Download PDFInfo
- Publication number
- JP2014041096A JP2014041096A JP2012184407A JP2012184407A JP2014041096A JP 2014041096 A JP2014041096 A JP 2014041096A JP 2012184407 A JP2012184407 A JP 2012184407A JP 2012184407 A JP2012184407 A JP 2012184407A JP 2014041096 A JP2014041096 A JP 2014041096A
- Authority
- JP
- Japan
- Prior art keywords
- saliva
- correlation
- related disease
- lifestyle
- support method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
本発明は、唾液検査を用いた生活習慣病判定方法に関する。より詳細には、ドクターの診断をまたずとも被験者が自ら判定を行える支援方法である。 The present invention relates to a lifestyle-related disease determination method using a saliva test. More specifically, this is a support method in which a subject can make a determination himself without diagnosing a doctor.
従来から、体液（血液、尿、唾液など）の酸化還元電位を測定し、病気や痛みの度合いを数値化し、健康値と疾病値の数値ゾーンを示して、被験者の健康と酸化還元電位値の健康目安を示すことが知られている（特許文献１参照）。 Conventionally, the redox potential of body fluids (blood, urine, saliva, etc.) is measured, the degree of illness or pain is quantified, the numerical value zone of the health value and disease value is shown, and the health and redox potential values of the subject are measured. It is known to show a health standard (see Patent Document 1).
また、脂溶性ビタミンなどの生体内移行を唾液から測定することが知られている（特許文献２参照）。 It is also known to measure in vivo migration of fat-soluble vitamins and the like from saliva (see Patent Document 2).
また、血液と唾液中のそれぞれのヒト脳型プロスタグランジンＤ合成酵素の濃度を測定し、虚血性疾患の検出をすることが知られている（特許文献３参照）。 It is also known to detect ischemic disease by measuring the concentration of each human brain type prostaglandin D synthase in blood and saliva (see Patent Document 3).
また、従来の唾液検査の問題点として、日内変動、日間変動、個人差が大きいと考えられている。また、口腔内病変の影響も受けることがあり、血液検査のように唾液検査のデータのみでは基準が決めにくいと考えられる。 Further, it is considered that there are large daily fluctuations, daily fluctuations, and individual differences as problems of the conventional saliva test. In addition, it may be affected by intraoral lesions, and it is considered that it is difficult to determine a standard based only on saliva test data as in blood tests.
そこで、唾液検査における唾液採取の方法を確立し、唾液検査でも血液検査のように判断基準を設定することが求められている。ところで、上記特許文献１から３は唾液と血液中の同じ成分を測定しており、同じ成分同士での相関を見ているにすぎず、唾液中の成分と異なる血液の成分とを測定しておいて、それらの相関を求めるものではない。 Therefore, it is required to establish a method for collecting saliva in the saliva test, and to set a judgment standard in the saliva test as in the blood test. By the way, the above-mentioned patent documents 1 to 3 measure the same component in saliva and blood, and only look at the correlation between the same components, and measure the components in blood different from the components in saliva. However, the correlation between them is not obtained.
本発明は、上記の課題に鑑みてなされたものであって、唾液に関する所定の第１測定結果（例えば所定成分の測定値）と、前記唾液に関する所定の第１測定結果とは異なる、血液に関する所定の第２測定結果（例えば所定成分の測定値）とをそれぞれ測定して互いの相関を予め求め、この相関を用いて、日々の唾液検査から生活習慣病（予備軍、進行状況を含む）を判定することができる生活習慣病判定支援方法を提供する。 This invention is made in view of said subject, Comprising: The predetermined | prescribed 1st measurement result (for example, measured value of a predetermined component) regarding saliva differs from the predetermined | prescribed 1st measurement result regarding the said saliva regarding blood A predetermined second measurement result (for example, a measured value of a predetermined component) is measured to obtain a correlation with each other in advance, and a daily-related saliva test is used to determine a lifestyle-related disease (including reserve forces and progress). A lifestyle-related disease determination support method is provided.
上記課題を解決するために、鋭意研究を重ねた結果、以下の本発明を完成するに至ったものである。すなわち、本発明は、唾液に基づいて生活習慣病を判定する生活習慣病判定支援方法であって、
唾液中の所定成分と、当該唾液中の所定成分と異なる血液中の所定成分との第１相関関係を予め求める第１準備工程と、
唾液検査をする場合に、唾液を採取する採取工程と、
前記採取工程で採取された唾液中の所定成分を測定する成分測定工程と、
前記成分測定工程で測定された唾液中の所定成分の測定値と、前記第１準備工程で予め求められた第１相関関係に基づき、生活習慣病を判定する第１判定工程と、を含む。
As a result of intensive studies in order to solve the above problems, the present invention has been completed. That is, the present invention is a lifestyle disease determination support method for determining lifestyle diseases based on saliva,
A first preparation step for obtaining in advance a first correlation between a predetermined component in saliva and a predetermined component in blood different from the predetermined component in saliva;
When performing a saliva test, a collection process for collecting saliva;
A component measuring step for measuring a predetermined component in the saliva collected in the collecting step;
A first determination step of determining a lifestyle-related disease based on the measured value of the predetermined component in the saliva measured in the component measurement step and the first correlation obtained in advance in the first preparation step.
この構成によれば、唾液に関する所定の第１測定結果（所定成分の測定値）と、前記唾液に関する所定の第１測定結果とは異なる、血液に関する所定の第２測定結果（所定成分の測定値）とをそれぞれ測定して互いの相関（第１相関関係）を予め求めておく。そして、日々の唾液測定を行い、測定結果と、予め求められている相関関係から、生活習慣病を判定できる。唾液検査であるため、測定者自身が簡便に行え、また、血液検査のために病院へ行く必要もなく、生活習慣病の判定結果を短時間で得られる（血液検査は短時間で行えない場合もある）。 According to this configuration, the predetermined first measurement result (measured value of the predetermined component) related to blood, which is different from the predetermined first measurement result (measured value of the predetermined component) related to saliva, and the predetermined first measurement result related to the saliva. ) And the respective correlations (first correlation) are obtained in advance. And daily saliva measurement is performed, and a lifestyle-related disease can be determined from a measurement result and the correlation calculated | required previously. Because it is a saliva test, it is easy for the measurer himself / herself, and it is not necessary to go to the hospital for a blood test, and it is possible to obtain the judgment result of lifestyle-related diseases in a short time (when the blood test cannot be performed in a short time) There is also.)
上記本発明の一実施形態として、前記第１相関関係は、前記唾液中の所定成分がアミラーゼである場合に前記血液中の所定成分がトリグリセライドであり、前記第１判定工程は、高脂血症を判定する構成である。高脂血症に対するトリグリセライドの基準値（正常範囲、異常範囲）に相当するアミラーゼの基準値（正常範囲、異常範囲）がわかるので、アミラーゼの値から高脂血症を判定できる。 In one embodiment of the present invention, the first correlation is that when the predetermined component in the saliva is amylase, the predetermined component in the blood is triglyceride, and the first determination step includes hyperlipidemia. It is the structure which determines. Since the reference value (normal range, abnormal range) of amylase corresponding to the reference value (normal range, abnormal range) of triglyceride for hyperlipidemia is known, hyperlipidemia can be determined from the value of amylase.
これによって、血液中のトリグリセライドと唾液中のアミラーゼとの相関関係に基づいて、唾液検査から高脂血症を簡単に判定できる。また、その他の脂質異常症も判断できる。 Thus, hyperlipidemia can be easily determined from a saliva test based on the correlation between triglyceride in blood and amylase in saliva. In addition, other dyslipidemia can be determined.
上記本発明の一実施形態として、前記第１相関関係は、前記唾液中の所定成分がＩｇＡである場合に前記血液中の所定成分が尿酸であり、前記第１判定工程は、痛風を判定する構成である。痛風に対する尿酸の基準値（正常範囲、異常範囲）に相当するＩｇＡの基準値（正常範囲、異常範囲）がわかるので、ＩｇＡの値から痛風を判定できる。 As one embodiment of the present invention, the first correlation is that when the predetermined component in the saliva is IgA, the predetermined component in the blood is uric acid, and the first determination step determines gout. It is a configuration. Since the reference value (normal range, abnormal range) of IgA corresponding to the reference value (normal range, abnormal range) of uric acid for gout is known, gout can be determined from the IgA value.
これによって、血液中の尿酸と唾液中のＩｇＡとの相関関係に基づいて、唾液検査から痛風を簡単に判定できる。 Thus, gout can be easily determined from a saliva test based on the correlation between uric acid in blood and IgA in saliva.
上記本発明の一実施形態として、前記生活習慣病判定支援方法は、
唾液のｐＨと血液中の所定成分との第２相関関係を予め求める第２準備工程と、
前記採取工程で採取された唾液のｐＨを測定するｐＨ測定工程と、
前記ｐＨ測定工程で測定された唾液のｐＨと、前記第２準備工程で予め求められた第２相関関係に基づき、生活習慣病を判定する第２判定工程と、をさらに含む構成である。
As one embodiment of the present invention, the lifestyle-related disease determination support method comprises:
A second preparatory step for obtaining in advance a second correlation between the pH of saliva and a predetermined component in blood;
A pH measuring step for measuring the pH of saliva collected in the collecting step;
It is the structure further including the 2nd determination process which determines lifestyle-related disease based on the pH of the saliva measured at the said pH measurement process, and the 2nd correlation previously calculated | required by the said 2nd preparation process.
この構成によって、唾液に関する所定の第２測定結果（ｐＨ値）と、前記唾液に関する所定の第２測定結果とは異なる、血液に関する所定の第２測定結果（所定成分の測定値）とをそれぞれ測定して互いの相関（第２相関関係）を予め求めておく。そして、日々の唾液測定を行い、測定結果と、予め求められている相関関係から、生活習慣病を判定できる。 With this configuration, a predetermined second measurement result (pH value) related to saliva and a predetermined second measurement result related to blood (measured values of predetermined components) different from the predetermined second measurement result related to saliva are measured. Thus, a mutual correlation (second correlation) is obtained in advance. And daily saliva measurement is performed, and a lifestyle-related disease can be determined from a measurement result and the correlation calculated | required previously.
上記本発明の一実施形態として、前記第２相関関係は、前記血液中の所定成分がトリグリセライドであり、前記第２判定工程は、高脂血症を判定する構成である。高脂血症に対するトリグリセライドの基準値（正常範囲、異常範囲）に相当するｐＨの基準値（正常範囲、異常範囲）がわかるので、ｐＨの値から高脂血症を判定できる。 As one embodiment of the present invention, the second correlation is such that the predetermined component in the blood is triglyceride, and the second determination step determines hyperlipidemia. Since the reference value of pH (normal range, abnormal range) corresponding to the reference value (normal range, abnormal range) of triglyceride for hyperlipidemia is known, hyperlipidemia can be determined from the pH value.
これによって、血液中のトリグリセライドと唾液のｐＨとの相関関係に基づいて、唾液検査から高脂血症を簡単に判定できる。 Thus, hyperlipidemia can be easily determined from a saliva test based on the correlation between triglyceride in blood and the pH of saliva.
上記本発明の一実施形態として、前記生活習慣病判定支援方法は、
唾液中の所定成分と血圧との第３相関関係を予め求める第３準備工程をさらに含み、
前記判定工程は、前記成分測定工程で測定された唾液中の所定成分の測定値と、前記第３準備工程で予め求められた第３相関関係に基づき、生活習慣病をさらに判定する構成である。
As one embodiment of the present invention, the lifestyle-related disease determination support method comprises:
A third preparatory step for obtaining in advance a third correlation between a predetermined component in saliva and blood pressure;
The determination step is configured to further determine lifestyle-related diseases based on the measured value of the predetermined component in saliva measured in the component measurement step and the third correlation obtained in advance in the third preparation step. .
この構成によって、唾液に関する所定の第３測定結果（所定成分の測定値）と、前記唾液に関する所定の第３測定結果とは異なる、血液に関する所定の第３測定結果（血圧）とをそれぞれ測定して互いの相関（第３相関関係）を予め求めておく。そして、日々の唾液測定を行い、測定結果と、予め求められている相関関係から、生活習慣病を判定できる。 With this configuration, a predetermined third measurement result (blood pressure) relating to blood, which is different from a predetermined third measurement result relating to saliva, and a predetermined third measurement result relating to blood, which are different from the predetermined third measurement result relating to saliva, are measured. Thus, a mutual correlation (third correlation) is obtained in advance. And daily saliva measurement is performed, and a lifestyle-related disease can be determined from a measurement result and the correlation calculated | required previously.
上記本発明の一実施形態として、前記第３相関関係は、前記唾液中の所定成分がアミラーゼであり、前記第３判定工程は、高血圧を判定する構成である。高血圧の基準値（正常範囲、異常範囲）に相当するアミラーゼの基準値（正常範囲、異常範囲）がわかるので、アミラーゼの値から高血圧を判定できる。 As one embodiment of the present invention, the third correlation is such that the predetermined component in the saliva is amylase, and the third determination step determines hypertension. Since the reference value (normal range, abnormal range) of amylase corresponding to the reference value (normal range, abnormal range) of hypertension is known, hypertension can be determined from the amylase value.
これによって、血圧と唾液中のアミラーゼとの相関関係に基づいて、唾液検査から高血圧を簡単に判定できる。 Accordingly, hypertension can be easily determined from a saliva test based on the correlation between blood pressure and amylase in saliva.
上記本発明の一実施形態として、前記生活習慣病判定支援方法は、
唾液中のＩｇＡと唾液のｐＨとの第４相関関係を予め求める第４準備工程と、
唾液中のＩｇＡまたは唾液のｐＨのいずれか一方の測定をすることで、他方に対応した生活習慣病を判定する第４判定工程と、をさらに含む構成である。
As one embodiment of the present invention, the lifestyle-related disease determination support method comprises:
A fourth preparation step for obtaining a fourth correlation between IgA in saliva and pH of saliva in advance;
And a fourth determination step of determining a lifestyle-related disease corresponding to the other by measuring either IgA in saliva or pH of saliva.
これによって、この第４相関関係に基づいて、唾液のｐＨによらず唾液中のＩｇＡから高脂血症を判定でき、一方、唾液中のＩｇＡによらず唾液のｐＨから痛風を判定できる。 Thereby, based on this fourth correlation, hyperlipidemia can be determined from IgA in saliva regardless of the pH of saliva, while gout can be determined from pH of saliva regardless of IgA in saliva.
上記本発明の一実施形態として、前記生活習慣病判定支援方法は、
唾液中のＩｇＡとアミラーゼとの第５相関関係を予め求める第５準備工程と、
唾液中のＩｇＡまたはアミラーゼのいずれか一方の測定をすることで、他方に対応した生活習慣病を判定する第５判定工程と、をさらに含む構成である。
As one embodiment of the present invention, the lifestyle-related disease determination support method comprises:
A fifth preparatory step for obtaining in advance a fifth correlation between IgA and amylase in saliva;
And a fifth determination step of determining a lifestyle-related disease corresponding to the other by measuring either IgA or amylase in saliva.
これによって、この第５相関関係に基づいて、唾液中のアミラーゼによらず唾液中のＩｇＡから高脂血症を判定でき、一方、唾液中のＩｇＡによらず唾液中のアミラーゼから痛風を判定できる。 Thereby, based on this fifth correlation, hyperlipidemia can be determined from IgA in saliva regardless of amylase in saliva, while gout can be determined from amylase in saliva regardless of IgA in saliva. .
上記本発明の一実施形態として、前記それぞれの準備工程で採取される唾液サンプルは、所定日数の間、歯磨き後所定時間後に採取する構成である。 As one embodiment of the present invention, the saliva sample collected in each of the preparation steps is configured to be collected for a predetermined number of days and after a predetermined time after brushing.
この構成によって、日内変動、日間変動を考慮した唾液と血液の相関関係を求めることができる。所定日数は、日間変動（体調のバラツキを相殺）を考慮して、例えば、３日以上が好ましく、５日以上がより好ましく、１０日以上がさらに好ましい。歯磨き後所定時間後は、日内変動（特に飲食物の影響）を考慮して、例えば、食事後（朝、昼、夜）歯磨きをして数時間後（１、２、３時間後など）、また、採取時間を１５時に設定しておき、歯磨きをその例えば数時間前に設定することが挙げられる。所定の被験者の相関関係を構築するためには、その被験者のデータでのみ相関関係を構築してもよい。一方、汎用性のある唾液―血液の相関関係を構築するためには、個人差を考慮して、複数人以上のデータで構築する必要があり、例えば、１０人以上、１５人以上、２０人以上が好ましい。また、相関関係は、男、女の別、年代別で異なる構築が好ましい。 With this configuration, it is possible to obtain a correlation between saliva and blood in consideration of daily fluctuations and daily fluctuations. The predetermined number of days is preferably, for example, 3 days or more, more preferably 5 days or more, and even more preferably 10 days or more in consideration of daily fluctuations (cancelling variation in physical condition). After a predetermined time after brushing, considering daily fluctuations (especially the influence of food and drink), for example, after a meal (morning, noon, night) brushing a few hours (after 1, 2, 3 hours, etc.) In addition, the sampling time may be set at 15:00, and the toothpaste may be set, for example, several hours before that. In order to construct the correlation of a predetermined subject, the correlation may be constructed only with the data of the subject. On the other hand, in order to construct a general saliva-blood correlation, it is necessary to construct with data of more than one person in consideration of individual differences. For example, 10 or more, 15 or more, 20 The above is preferable. In addition, it is preferable that the correlation be different for each man and woman and for each age group.
また、他の発明は、唾液に基づいて生活習慣病を判定する生活習慣病判定支援システムであって、
唾液に関する所定の測定結果と、前記唾液に関する所定の測定結果とは異なる、血液に関する所定の測定結果との間の相関関係を予め保存している相関関係保存部と、
被験者の唾液を検査し、唾液に関する所定の測定結果を得る唾液検査部と、
前記唾液検査部で得られた唾液に関する所定の測定結果と、前記相関関係保存部に保存されている相関関係に基づき、生活習慣病を判定する判定部と、
前記判定部で判定された結果を出力する出力部と、を有する。
Another invention is a lifestyle-related disease determination support system for determining a lifestyle-related disease based on saliva,
A correlation storage unit that stores in advance a correlation between a predetermined measurement result related to saliva and a predetermined measurement result related to blood different from the predetermined measurement result related to saliva;
Inspecting the subject's saliva and obtaining a predetermined measurement result related to saliva;
A determination unit for determining lifestyle-related diseases based on a predetermined measurement result relating to saliva obtained by the saliva test unit and a correlation stored in the correlation storage unit;
And an output unit that outputs a result determined by the determination unit.
この構成によれば、日々の唾液測定を行い、この測定結果と、予め求められている相関関係から生活習慣病を判定し、出力（モニターに表示、外部装置へ送信、記憶媒体に記憶、印刷を含む）をすることができる。「唾液に関する所定の測定結果」は、例えば、ｐＨ、アミラーゼ、ＩｇＡが挙げられる。「血液に関する所定の測定結果」は、例えば、トリグリセライド、血圧、尿酸が挙げられる。 According to this configuration, daily saliva measurement is performed, lifestyle-related diseases are determined from the measurement results and correlations obtained in advance, and output (displayed on a monitor, transmitted to an external device, stored in a storage medium, printed Can be included). Examples of the “predetermined measurement result regarding saliva” include pH, amylase, and IgA. Examples of the “predetermined measurement result related to blood” include triglyceride, blood pressure, and uric acid.
相関関係保存部は、例えば、記憶媒体（各種メディア）、コンピュータのＨＤＤなどである。判定部は、例えば、コンピュータのＣＰＵ、メモリなどのハードウエア構成およびソフトウエアプログラムとの組合構成、専用回路、ファームウエアなどで構成できる。唾液検査部は、例えば、ｐＨ測定器、アミラーゼ測定器であり、判定部に測定データを送信し、判定部が受信した測定データに基づいて上記判定を実施することができる。あるいは、コンピュータの入力部を用いて各種測定データ（ｐＨ，アミラーゼ、ＩｇＡ）を入力し、あるいは通信部から各種測定データを受信して、コンピュータの一構成要素としての判定部が上記判定を実施することができる。 The correlation storage unit is, for example, a storage medium (various media), a computer HDD, or the like. The determination unit can be configured by, for example, a hardware configuration such as a CPU and a memory of a computer and a combination configuration with a software program, a dedicated circuit, firmware, and the like. A saliva test | inspection part is a pH measuring device and an amylase measuring device, for example, transmits measurement data to a determination part, and can implement the said determination based on the measurement data which the determination part received. Alternatively, various measurement data (pH, amylase, IgA) are input using the input unit of the computer, or various measurement data are received from the communication unit, and the determination unit as one component of the computer performs the above determination. be able to.
本実施形態において以下に説明するが、本発明は以下の内容に限定されるものではない。 Although the present embodiment will be described below, the present invention is not limited to the following contents.
（相関関係の構築）
まず、唾液と血液の相関関係を構築する。唾液提供者から健康診断データ、問診データを得て、健常者であることを確認する。血液サンプルと各種測定値は、健康診断の測定値を利用する。唾液の採取方法は以下の通りである。まず、昼食後に歯磨きをし、その後２時間後の１５時に唾液サンプルを採取する。これを、５日間連続で行う。
(Creation of correlation)
First, the correlation between saliva and blood is constructed. Obtain health checkup data and interview data from the saliva provider and confirm that they are healthy. The blood sample and various measurement values use the measurement values of the health checkup. The method for collecting saliva is as follows. First, brush your teeth after lunch, then take a saliva sample at 15:00, 2 hours later. This is done for 5 consecutive days.
（唾液検査）
採取した唾液サンプルの測定を行う。ｐＨ測定は、各種ｐＨ測定器を用いることができ、例えば堀場製作所製の「Ｔｗｉｎ ｐＨ」が挙げられる。また、アミラーゼ測定は、各種アミラーゼ測定器を用いることができ、例えば二プロ製「唾液アミラーゼモニター」が挙げられる。ＩｇＡ測定は、ＥＬＩＳＡ法による唾液中に含まれる抗体あるいは抗原の濃度を定量検出する。ＥＬＩＳＡ法は一般的な手法である。唾液サンプルは、上記採取方法で２４名から５日間採取する。極端に外れたデータは用いないものとできる。表１に５日間唾液サンプルの平均ｐＨ、平均アミラーゼ値、平均ＩｇＡ値を示す。空欄は唾液サンプル量が少なく測定できなかったためである。
(Saliva test)
The collected saliva sample is measured. Various pH measuring devices can be used for pH measurement, and examples thereof include “Twin pH” manufactured by Horiba. In addition, various amylase measuring instruments can be used for amylase measurement, for example, Nipro's “saliva amylase monitor”. In IgA measurement, the concentration of antibody or antigen contained in saliva by ELISA is quantitatively detected. The ELISA method is a general method. Saliva samples are collected for 5 days from 24 people by the above collection method. Extremely deviating data can not be used. Table 1 shows the average pH, average amylase value, and average IgA value of the 5-day saliva sample. This is because the amount of saliva sample was small and could not be measured.
（唾液検査結果と血液検査結果との相関関係）
まず、唾液サンプル全体（５日間平均値）についてピアソン相関係数の検定を行う。２変量の間の関連度合いを測る指標である相関係数を求め、相関係数の有意性を検定する。つまり、母相関係数ρ＝０を検定することで帰無仮説：「２変量の間に相関はない」を検定する。また、母相関係数ρの１００（１−α）％信頼区間を表示し、ρの信頼区間に０が含まれないとき、ρ≒０を意味し、すなわち検定は有意であり、２変量の間に相関があるとみることができる。ここでは、具体的には相関関係の結果と判定は、相関係数を算出し、Ｐ値を算出し、信頼区間を算出する。Ｐ値において危険率５％以内であれば相関有意性があると判定する。
(Correlation between saliva test results and blood test results)
First, the Pearson correlation coefficient is tested for the entire saliva sample (average value over 5 days). A correlation coefficient that is an index for measuring the degree of association between two variables is obtained, and the significance of the correlation coefficient is tested. That is, the null hypothesis: “no correlation between two variables” is tested by testing the population correlation coefficient ρ = 0. Also, the 100 (1-α)% confidence interval of the population correlation coefficient ρ is displayed, and when 0 is not included in the confidence interval of ρ, it means that ρ≈0, that is, the test is significant, and the bivariate It can be seen that there is a correlation between them. Specifically, in the correlation result and determination, a correlation coefficient is calculated, a P value is calculated, and a confidence interval is calculated. If the risk value is within 5% in the P value, it is determined that there is a correlation significance.
表２に有意な相関関係が認められた、ｐＨとトリグリセライド、アミラーゼと血圧（上の値）、アミラーゼとトリグリセライド、ＩｇＡと尿酸の各データを示す。 Table 2 shows data of pH and triglyceride, amylase and blood pressure (upper value), amylase and triglyceride, IgA and uric acid, in which a significant correlation was recognized.
表２に示すとおり、ｐＨとトリグリセライドは有意な正の相関が認められ、アミラーゼと血圧（上の値）は有意な負の相関が認められ、アミラーゼとトリグリセライドは有意な負の相関が認められ、ＩｇＡと尿酸は有意な負の相関が認められる。それぞれの唾液のデータは５日間の平均値を用いている。 As shown in Table 2, there was a significant positive correlation between pH and triglyceride, a significant negative correlation between amylase and blood pressure (upper value), and a significant negative correlation between amylase and triglyceride, There is a significant negative correlation between IgA and uric acid. Each saliva data uses an average value for 5 days.
（唾液検査項目間の相関関係）
表３に相関関係が認められた、ＩｇＡとｐＨ、ＩｇＡとアミラーゼの各データを示す。
(Correlation between saliva test items)
Table 3 shows data of IgA and pH, and IgA and amylase, in which correlations were recognized.
表３に示すとおり、ＩｇＡとｐＨは明確な負の相関が認められ、ＩｇＡとアミラーゼも明確な正の相関が認められる。 As shown in Table 3, there is a clear negative correlation between IgA and pH, and there is also a clear positive correlation between IgA and amylase.
（他の測定値を考慮したＩｇＡと尿酸の相関関係）
次に、ＩｇＡと尿酸値について、下記抽出サンプル群での相関関係を表４に示す。
(Correlation between IgA and uric acid considering other measured values)
Next, regarding the IgA and the uric acid value, the correlation in the following extracted sample group is shown in Table 4.
表４は、ｐＨが高群の人のＩｇＡと尿酸値の相関、アミラーゼが低群の人のＩｇＡと尿酸値の相関、酸化還元電位が低群の人のＩｇＡと尿酸値の相関、血糖値が低群の人のＩｇＡと尿酸値の相関を示している。それぞれの指標の全データの平均値を境に高群と低群とに分けた。ｐＨの高群において、ＩｇＡと尿酸との相関係数が「−０．８６６」と絶対値が１に近づき、その高群において低群よりも高い相関が認められた。また、アミラーゼの低群において、ＩｇＡと尿酸との相関係数が「−０．９４１」と絶対値が１に近づき、その低群において高群よりも高い相関が認められた。また、血液サンプル全体の血糖値の平均値を境に高群と低群とに分け、血糖値の高群において、ＩｇＡと尿酸との相関係数が「−０．８４３」と絶対値が１に近づき、その高群において低群よりも高い相関が認められた。また、唾液サンプル全体の酸化還元電位の平均値を境に高群と低群とに分け、酸化還元電位の低群において、ＩｇＡと尿酸との相関係数が「−０．９７９」と絶対値が１に近づき、その低群において高群よりも高い相関が認められた。なお、酸化還元電位は、塩化銀電極（基準極）と白金電極（作用極）による電気化学測定法によって測定される。 Table 4 shows the correlation between IgA and uric acid levels in people with high pH, correlation between IgA and uric acid levels in people with low amylase, correlation between IgA and uric acid levels in people with low redox potential, blood glucose levels Shows the correlation between IgA and uric acid levels in the low group. The average value of all data of each index was divided into high group and low group on the boundary. In the high pH group, the correlation coefficient between IgA and uric acid was “−0.866”, and the absolute value approached 1, and a higher correlation was observed in the high group than in the low group. In the low group of amylase, the correlation coefficient between IgA and uric acid was “−0.941” and the absolute value approached 1, and a higher correlation was observed in the low group than in the high group. In addition, the blood glucose level is divided into a high group and a low group on the basis of the average blood glucose level of the whole blood sample. In the high blood glucose group, the correlation coefficient between IgA and uric acid is “−0.843” and the absolute value is 1. The higher group showed a higher correlation than the lower group. In addition, the average value of the redox potential of the whole saliva sample is divided into a high group and a low group, and in the low group of the redox potential, the correlation coefficient between IgA and uric acid is “−0.979” and an absolute value. Was close to 1, and a higher correlation was observed in the low group than in the high group. The oxidation-reduction potential is measured by an electrochemical measurement method using a silver chloride electrode (reference electrode) and a platinum electrode (working electrode).
（判定フロー）
上記の結果から、相関関係が予め得られる。次に、被験者の唾液を検査するために、唾液サンプルを採取する。唾液採取は上記と同じ採取方法が好ましく、検査したい日の歯磨後数時間後（例えば１５時）が好ましい。次いで、採取した唾液を測定する。例えば、ｐＨ測定器で唾液サンプルのｐＨを測定する。また、アミラーゼ測定器で唾液サンプルのアミラーゼを測定する。また、ＥＬＩＳＡ法でＩｇＡを測定する。次に、上記で測定された各種測定値と、上記で予め得られている相関関係に基づき、生活習慣病を判定する。判定された結果は、出力される。出力は、例えば、モニター表示、他の記憶媒体への保存、印刷、他の情報処理装置への送信などが挙げられる。
(Judgment flow)
From the above results, the correlation is obtained in advance. Next, in order to examine the saliva of the subject, a saliva sample is collected. Saliva collection is preferably performed in the same manner as described above, and preferably several hours after dentifrice on the day to be examined (for example, 15:00). Next, the collected saliva is measured. For example, the pH of the saliva sample is measured with a pH meter. Further, amylase in the saliva sample is measured with an amylase measuring instrument. Moreover, IgA is measured by ELISA method. Next, lifestyle-related diseases are determined based on the various measured values measured above and the correlation obtained in advance. The determined result is output. Examples of the output include monitor display, saving to another storage medium, printing, transmission to another information processing apparatus, and the like.
本実施形態では、ｐＨまたはアミラーゼから高脂血症が判定できる。また、ｐＨとアミラーゼに基づいて同じ高脂血症が判定できるが、いずれか一方の指標でのみ高脂血症が判定された場合には、低いレベルで高脂血症性であると判定され、両指標で高脂血症が判定された場合には、高いレベルで高脂血症性であると判定することができる。すなわち、異なる２指標を用いて段階的に判定をすることができる。 In this embodiment, hyperlipidemia can be determined from pH or amylase. Also, the same hyperlipidemia can be determined based on pH and amylase, but if hyperlipidemia is determined only by one of the indicators, it is determined to be hyperlipidemic at a low level. When hyperlipidemia is determined by both indices, it can be determined that the hyperlipidemia is at a high level. That is, the determination can be made step by step using two different indexes.
また、ＩｇＡから通風が判定でき、アミラーゼから高血圧であるか否かを判定できる。 Moreover, ventilation can be determined from IgA, and it can be determined from amylase whether it is hypertension.
また、ｐＨとＩｇＡあるいはアミラーゼとＩｇＡの相関関係から、ｐＨまたはアミラーゼに基づいて通風を判定できる。また、ｐＨまたはアミラーゼに基づいて（ＩｇＡとの相関関係を介して）同じ痛風が判定できるが、いずれか一方の指標でのみ通風が判定された場合には、低いレベルで通風であると判定され、両指標で痛風が判定された場合には、高いレベルで通風であると判定することができる。これによればＩｇＡの測定をすることなく、通風を判定できる。 Further, ventilation can be determined based on pH or amylase from the correlation between pH and IgA or amylase and IgA. The same gout can be determined based on pH or amylase (via correlation with IgA), but if ventilation is determined only with one of the indicators, it is determined that the ventilation is at a low level. When gout is determined by both indicators, it can be determined that the ventilation is at a high level. According to this, ventilation can be determined without measuring IgA.
また、ｐＨとＩｇＡあるいはアミラーゼとＩｇＡの相関関係から、ＩｇＡからも高脂血症を判定できる。すなわち、３指標に基づいて高脂血症を判定することができる。 Hyperlipidemia can also be determined from IgA based on the correlation between pH and IgA or amylase and IgA. That is, hyperlipidemia can be determined based on the three indices.
以上、本実施形態によれば、血液検査によらず、唾液に関する測定結果と、予め求められている血液と唾液との相関関係から、生活習慣病を簡単に判定できる。
As described above, according to the present embodiment, it is possible to easily determine a lifestyle-related disease from the measurement result related to saliva and the correlation between blood and saliva obtained in advance, regardless of the blood test.
Claims (10)
唾液中の所定成分と、当該唾液中の所定成分と異なる血液中の所定成分との第１相関関係を予め求める第１準備工程と、
唾液検査をする場合に、唾液を採取する採取工程と、
前記採取工程で採取された唾液中の所定成分を測定する成分測定工程と、
前記成分測定工程で測定された唾液中の所定成分の測定値と、前記第１準備工程で予め求められた第１相関関係に基づき、生活習慣病を判定する第１判定工程と、を含む生活習慣病判定支援方法。 A lifestyle-related disease determination support method for determining lifestyle-related diseases based on saliva,
A first preparation step for obtaining in advance a first correlation between a predetermined component in saliva and a predetermined component in blood different from the predetermined component in saliva;
When performing a saliva test, a collection process for collecting saliva;
A component measuring step for measuring a predetermined component in the saliva collected in the collecting step;
A life including a measurement value of a predetermined component in saliva measured in the component measurement step and a first determination step of determining a lifestyle-related disease based on a first correlation obtained in advance in the first preparation step Habitual disease determination support method.
前記第１判定工程は、高脂血症を判定する、請求項１に記載の生活習慣病判定支援方法。 The first correlation is that when the predetermined component in the saliva is amylase, the predetermined component in the blood is triglyceride,
The lifestyle-related disease determination support method according to claim 1, wherein the first determination step determines hyperlipidemia.
前記第１判定工程は、痛風を判定する、請求項１または２に記載の生活習慣病判定支援方法。 The first correlation is that when the predetermined component in the saliva is IgA, the predetermined component in the blood is uric acid,
The lifestyle-related disease determination support method according to claim 1 or 2, wherein the first determination step determines gout.
唾液のｐＨと血液中の所定成分との第２相関関係を予め求める第２準備工程と、
前記採取工程で採取された唾液のｐＨを測定するｐＨ測定工程と、
前記ｐＨ測定工程で測定された唾液のｐＨと、前記第２準備工程で予め求められた第２相関関係に基づき、生活習慣病を判定する第２判定工程と、をさらに含む請求項１から３のいずれか１項に記載の生活習慣病判定支援方法。 The lifestyle-related disease determination support method includes:
A second preparatory step for obtaining in advance a second correlation between the pH of saliva and a predetermined component in blood;
A pH measuring step for measuring the pH of saliva collected in the collecting step;
The second determination step of determining a lifestyle-related disease based on the saliva pH measured in the pH measurement step and the second correlation obtained in advance in the second preparation step. The lifestyle-related disease determination support method according to any one of the above.
前記第２判定工程は、高脂血症を判定する、請求項４に記載の生活習慣病判定支援方法。 In the second correlation, the predetermined component in the blood is triglyceride,
The lifestyle-related disease determination support method according to claim 4, wherein the second determination step determines hyperlipidemia.
唾液中の所定成分と血圧との第３相関関係を予め求める第３準備工程をさらに含み、
前記判定工程は、前記成分測定工程で測定された唾液中の所定成分の測定値と、前記第３準備工程で予め求められた第３相関関係に基づき、生活習慣病をさらに判定する、請求項１から５のいずれか１項に記載の生活習慣病判定支援方法。 The lifestyle-related disease determination method includes:
A third preparatory step for obtaining in advance a third correlation between a predetermined component in saliva and blood pressure;
The determination step further determines a lifestyle-related disease based on a measured value of a predetermined component in saliva measured in the component measurement step and a third correlation obtained in advance in the third preparation step. The lifestyle-related disease determination support method according to any one of 1 to 5.
前記第３判定工程は、高血圧を判定する、請求項６に記載の生活習慣病判定支援方法。 In the third correlation, the predetermined component in the saliva is amylase,
The lifestyle-related disease determination support method according to claim 6, wherein the third determination step determines hypertension.
唾液中のＩｇＡと唾液のｐＨとの第４相関関係を予め求める第４準備工程と、
唾液中のＩｇＡまたは唾液のｐＨのいずれか一方の測定をすることで、他方に対応した生活習慣病を判定する第４判定工程と、をさらに含む、請求項１〜７のいずれか１項に記載の生活習慣病判定支援方法。 The lifestyle-related disease determination support method includes:
A fourth preparation step for obtaining a fourth correlation between IgA in saliva and pH of saliva in advance;
The 4th determination process which further determines the lifestyle-related disease corresponding to the other by measuring any one of IgA in saliva or the pH of saliva in any one of Claims 1-7. The lifestyle-related disease determination support method described.
唾液中のＩｇＡとアミラーゼとの第５相関関係を予め求める第５準備工程と、
唾液中のＩｇＡまたはアミラーゼのいずれか一方の測定をすることで、他方に対応した生活習慣病を判定する第５判定工程と、をさらに含む、請求項１〜８のいずれか１項に記載の生活習慣病判定支援方法。 The lifestyle-related disease determination support method includes:
A fifth preparatory step for obtaining in advance a fifth correlation between IgA and amylase in saliva;
The method according to any one of claims 1 to 8, further comprising: a fifth determination step of determining a lifestyle-related disease corresponding to the other by measuring either IgA or amylase in saliva. Lifestyle-related disease determination support method.
The lifestyle-related disease determination support method according to any one of claims 1 to 9, wherein the saliva sample collected in each of the preparation steps is collected after a predetermined time after brushing for a predetermined number of days.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012184407A JP6117499B2 (en) | 2012-08-23 | 2012-08-23 | Lifestyle-related disease determination support method using saliva test |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012184407A JP6117499B2 (en) | 2012-08-23 | 2012-08-23 | Lifestyle-related disease determination support method using saliva test |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014041096A true JP2014041096A (en) | 2014-03-06 |
| JP6117499B2 JP6117499B2 (en) | 2017-04-19 |
Family
ID=50393455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012184407A Active JP6117499B2 (en) | 2012-08-23 | 2012-08-23 | Lifestyle-related disease determination support method using saliva test |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6117499B2 (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH095321A (en) * | 1995-06-23 | 1997-01-10 | Brother Ind Ltd | Biochemical substance measuring instrument and saliva collecting method applied to it |
| JP2003531375A (en) * | 2000-04-14 | 2003-10-21 | ライフポイント インコーポレイテッド | Detector for sample related to sample pH |
| JP2004219309A (en) * | 2003-01-16 | 2004-08-05 | Sapporo Imuno Diagnostic Laboratory:Kk | Method and kit for measuring saliva sugar |
| JP2004350861A (en) * | 2003-05-28 | 2004-12-16 | Tanita Corp | Health management device |
| JP2005140618A (en) * | 2003-11-06 | 2005-06-02 | Lion Corp | Method for estimating fluctuation of biochemical parameter, and method for predicting onset risk of lifestyle-related disease |
| JP2007033410A (en) * | 2005-07-29 | 2007-02-08 | Teikyo Univ | Disease examining method |
| WO2011104267A1 (en) * | 2010-02-25 | 2011-09-01 | Cor.Con. International S.R.L. | Method for determining the antioxidant power of biological and vegetal fluids |
| JP2011257148A (en) * | 2010-06-04 | 2011-12-22 | Teikyo Univ | Detection method |
| JP2012122788A (en) * | 2010-12-07 | 2012-06-28 | Lion Corp | Method for measuring adiponectin and/or insulin |
-
2012
- 2012-08-23 JP JP2012184407A patent/JP6117499B2/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH095321A (en) * | 1995-06-23 | 1997-01-10 | Brother Ind Ltd | Biochemical substance measuring instrument and saliva collecting method applied to it |
| JP2003531375A (en) * | 2000-04-14 | 2003-10-21 | ライフポイント インコーポレイテッド | Detector for sample related to sample pH |
| JP2004219309A (en) * | 2003-01-16 | 2004-08-05 | Sapporo Imuno Diagnostic Laboratory:Kk | Method and kit for measuring saliva sugar |
| JP2004350861A (en) * | 2003-05-28 | 2004-12-16 | Tanita Corp | Health management device |
| JP2005140618A (en) * | 2003-11-06 | 2005-06-02 | Lion Corp | Method for estimating fluctuation of biochemical parameter, and method for predicting onset risk of lifestyle-related disease |
| JP2007033410A (en) * | 2005-07-29 | 2007-02-08 | Teikyo Univ | Disease examining method |
| WO2011104267A1 (en) * | 2010-02-25 | 2011-09-01 | Cor.Con. International S.R.L. | Method for determining the antioxidant power of biological and vegetal fluids |
| JP2013520665A (en) * | 2010-02-25 | 2013-06-06 | コル．コン．インターナショナル ソシエタ ア レスポンサビリタ リミタータ | Methods for determining the antioxidant capacity of biological and vegetable fluids |
| JP2011257148A (en) * | 2010-06-04 | 2011-12-22 | Teikyo Univ | Detection method |
| JP2012122788A (en) * | 2010-12-07 | 2012-06-28 | Lion Corp | Method for measuring adiponectin and/or insulin |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6117499B2 (en) | 2017-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abell et al. | Assessing cortisol from hair samples in a large observational cohort: The Whitehall II study | |
| Schrack et al. | Assessing daily physical activity in older adults: unraveling the complexity of monitors, measures, and methods | |
| JP6117552B2 (en) | Lifestyle-related disease determination support device and lifestyle-related disease determination support system | |
| Hozawa et al. | Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama study | |
| Reich et al. | Visual analogue scale: evaluation of the instrument for the assessment of pruritus | |
| Godwin et al. | Manual and automated office measurements in relation to awake ambulatory blood pressure monitoring | |
| Verweij et al. | Measurement error of waist circumference: gaps in knowledge | |
| Rousham et al. | Significant changes in physical activity among pregnant women in the UK as assessed by accelerometry and self-reported activity | |
| Waldréus et al. | Thirst in the elderly with and without heart failure | |
| Hoyle et al. | Volaemic assessment of the elderly hyponatraemic patient: reliability of clinical assessment and validation of bioelectrical impedance analysis | |
| Kafri et al. | Multi-frequency bioelectrical impedance analysis for assessing fat mass and fat-free mass in stroke or transient ischaemic attack patients | |
| Park et al. | Design of a portable urine glucose monitoring system for health care | |
| Strauss et al. | The potential for glycemic control monitoring and screening for diabetes at dental visits using oral blood | |
| Roberts et al. | Protocol for measurement of mean arterial pressure at 10–40 weeks’ gestation | |
| Brown et al. | Can we use the Omron T9P automated blood pressure monitor in pregnancy? | |
| Crespo et al. | Clinical application of a novel automatic algorithm for actigraphy-based activity and rest period identification to accurately determine awake and asleep ambulatory blood pressure parameters and cardiovascular risk | |
| El Mokadem et al. | Correlation between blood pressure variability and subclinical target organ damage in patients with essential hypertension | |
| De Leon et al. | A population-based perspective of changes in health-related quality of life after myocardial infarction in older men and women | |
| Tirimacco et al. | Should capillary blood glucose measurements be used in population surveys? | |
| Prasad et al. | Fortnightly Review: Ambulatory blood pressure monitoring: a guide for general practitioners | |
| Laugesen et al. | Reproducibility of pulse wave analysis and pulse wave velocity in patients with type 2 diabetes | |
| Surkan et al. | Neuropsychological function in school-age children with low mercury exposures | |
| Grajda et al. | Preschool children blood pressure percentiles by age and height | |
| Malbora et al. | Ambulatory blood pressure monitoring of healthy schoolchildren with a family history of hypertension | |
| Di Bonito et al. | A new index to simplify the screening of hypertension in overweight or obese youth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150817 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160607 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160608 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160801 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161226 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170310 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170323 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6117499 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |